CRS is a known complication of T-cell redirecting therapy, observed in patients receiving CAR-T and/or bispecific antibodies, with clinical manifestations a result of an exuberant immune activation and concomitant proinflammatory cytokine production. Makita et al.²⁰  Grading is predicated on progressive symptoms from the hyperinflammatory state ranging from fevers to the development of hypoxia and vasodilatory mediated hypotension. Stepwise but rapid escalation of therapy is needed according to the severity of symptoms and is critical to avoid adverse clinical outcomes.